The abstract is read at the publisher; the summary is JClub's.
In 29 patient-derived and established tumor spheroid models, pan-RAS(ON) daraxonrasib (RMC-6236) suppressed growth across diverse RAS alterations and wild-type RAS.
- Why it matters: RAS alterations are common, but effective combination strategies require evidence that variant-selective and pan-RAS inhibition translate into measurable multi-cell-type tumor responses.
- What they did: The study tested four RAS inhibitors with pathway-directed agents in 7-day viability and longitudinal spheroid volume assays using multi-cell-type spheroids (malignant 60%, endothelial 25%, mesenchymal stem cells 15%).
- The result: All four RAS inhibitors showed positive Bliss scores with SHP2 inhibition and reduced viability and spheroid volume, while daraxonrasib plus cobimetinib was mostly additive with localized synergy and PI3K-AKT-mTOR combinations were often additive.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.